Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002921 · ClinicalTrials.gov registry record · Phase 2
S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00002921: Clinical Trial Phase 2 study, sponsored by SWOG Cancer Research Network.
NCT00002921 is a Phase 2 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002921, a Phase 2 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Some tumors need growth factors produced by the body to keep growing. Suramin may interfere with the growth factor and stop the tumor from growing. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with stage III or stage IV adrenocortical cancer.
Interventions
- DRUG therapeutic hydrocortisone
- DRUG suramin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 1997-03 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
Why NCT00002921 stopped before completion
NCT00002921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which therapeutic hydrocortisone is the first listed.
NCT00002921 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002921 about?
NCT00002921 is a clinical study titled "S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery". RATIONALE: Some tumors need growth factors produced by the body to keep growing. Suramin may interfere with the growth factor and stop the tumor from growing. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with stage III or stage IV adrenocortical cancer.
What is the current status of trial NCT00002921?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 1997-03. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00002921?
The interventions under investigation include: therapeutic hydrocortisone (DRUG), suramin (DRUG).
Who is sponsoring clinical trial NCT00002921?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002921's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia